ATAD2 as a Cancer Target: Insights into Its Structure, Functions, Mechanisms, and Drug Development

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• ATPase family AAA domain-containing protein 2 (ATAD2) is an oncogene involved in chromatin remodeling and cancer progression.
• ATAD2, a bromodomain protein, plays a critical role in epigenetic modifications across various malignancies.

Purpose of the Study:

• To provide a comprehensive review of ATAD2's structure, function, and significance in cancer.
• To explore molecular strategies for suppressing ATAD2 expression and discuss their therapeutic implications.
• To highlight recent advancements in small-molecule inhibitors targeting ATAD2.

Main Methods:

• Review of structural features, functional roles, and biological significance of ATAD2.
• Analysis of genetic and pharmacological approaches to suppress ATAD2.
• In-depth examination of small-molecule inhibitors, including binding interactions and clinical translation challenges.
• Alanine scanning calculations on molecular dynamics (MD) trajectories of protein-ligand complexes.

Main Results:

• Crystallography and computational modeling have accelerated ATAD2 drug discovery.
• Alanine scanning provided critical insights into the ATAD2 binding interface.
• Emerging roles of ATAD2 in mediating resistance to cancer therapies were examined.

Conclusions:

• ATAD2 is a promising target for cancer therapy, with ongoing efforts to develop effective inhibitors.
• Further research is needed to optimize ATAD2 inhibition strategies and overcome clinical translation challenges.
• Understanding ATAD2's role in drug resistance is crucial for developing combination therapies.